MBP Stock Overview
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Protagenic Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.29 |
52 Week High | US$1.60 |
52 Week Low | US$0.80 |
Beta | 0.38 |
1 Month Change | -9.15% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 55.42% |
Recent News & Updates
Recent updates
Shareholder Returns
MBP | DE Biotechs | DE Market | |
---|---|---|---|
7D | 9.3% | 0.8% | 1.2% |
1Y | n/a | -24.4% | 2.0% |
Return vs Industry: Insufficient data to determine how MBP performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how MBP performed against the German Market.
Price Volatility
MBP volatility | |
---|---|
MBP Average Weekly Movement | 19.1% |
Biotechs Industry Average Movement | 4.9% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: MBP's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine MBP's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 2 | n/a | www.protagenic.com |
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company’s lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.
Protagenic Therapeutics, Inc. Fundamentals Summary
MBP fundamental statistics | |
---|---|
Market cap | €5.74m |
Earnings (TTM) | -€4.67m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.2x
P/E RatioIs MBP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MBP income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$5.00m |
Earnings | -US$5.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.13 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did MBP perform over the long term?
See historical performance and comparison